CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|Switzerland
$48.44
-0.71 (-1.44%)
Tangible Book
$20.04
Upcoming Data Readouts (5)
May 2026
Est. completion
P3Sickle Cell Disease
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649n=13
May 2026
Est. completion
P3Beta-Thalassemia
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195n=16
Jun 2027
Est. completion
P1Cardiovascular
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172n=90
Jan 2030
Est. completion
P1P2B-cell Lymphoma
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742n=120
Dec 2031
Est. completion
P1SLE (Systemic Lupus)
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542n=80